Scholarlink

Background <p>Hepatocellular carcinoma (HCC) outcomes remain suboptimal. Myeloid-derived suppressor cells (MDSCs) exhibit notable immunosuppressive and pro-tumorigenic properties. However, the relationship with HCC remains insufficiently explored.</p> Methods <p>Using TCGA data, we developed an MDSC-associated lncRNA prognostic model and a clinical nomogram. To explore the model’s mechanistic basis and clinical significance, enrichment analysis, tumor mutation burden (TMB) analysis, tumor microenvironment (TME) evaluation, immunotherapy response prediction, and drug sensitivity assessment were performed. RT-qPCR was utilized to confirm lncRNA expression.</p> Results <p>A 7-lncRNA prognostic signature was established. High-risk patients exhibited significantly worse survival (<i>p</i> &lt; 0.001). The nomogram demonstrated superior accuracy over models excluding the risk evaluation. Enrichment analysis exposed that metabolic and immune-associated pathways were predominant within low-risk cohort, while cell proliferation and gene expression regulation dominant across the high-risk population. Meanwhile, an increased TMB and a degraded TME appeared in the high-risk population. The drug responsiveness evaluation revealed that sorafenib, axitinib, and others exhibited enhanced effectiveness among the low-risk population. High-risk individuals displayed enhanced reactions to medications like staurosporine, savolitinib, and others.</p> Conclusions <p>The prognostic model constructed based on the seven MDSCs-associated lncRNAs showed good application value in assessing prognosis and guiding clinical therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification and external validation of a prognostic signature based on myeloid-derived suppressor cell-related lncRNAs for hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Tong Mu,
  • Shunyao Zhang,
  • Yun Zhong,
  • Zijian Zhou,
  • Lei Xie,
  • Yajie Zhou,
  • Wenxiong Zhang,
  • Liang Zhai

摘要

Background

Hepatocellular carcinoma (HCC) outcomes remain suboptimal. Myeloid-derived suppressor cells (MDSCs) exhibit notable immunosuppressive and pro-tumorigenic properties. However, the relationship with HCC remains insufficiently explored.

Methods

Using TCGA data, we developed an MDSC-associated lncRNA prognostic model and a clinical nomogram. To explore the model’s mechanistic basis and clinical significance, enrichment analysis, tumor mutation burden (TMB) analysis, tumor microenvironment (TME) evaluation, immunotherapy response prediction, and drug sensitivity assessment were performed. RT-qPCR was utilized to confirm lncRNA expression.

Results

A 7-lncRNA prognostic signature was established. High-risk patients exhibited significantly worse survival (p < 0.001). The nomogram demonstrated superior accuracy over models excluding the risk evaluation. Enrichment analysis exposed that metabolic and immune-associated pathways were predominant within low-risk cohort, while cell proliferation and gene expression regulation dominant across the high-risk population. Meanwhile, an increased TMB and a degraded TME appeared in the high-risk population. The drug responsiveness evaluation revealed that sorafenib, axitinib, and others exhibited enhanced effectiveness among the low-risk population. High-risk individuals displayed enhanced reactions to medications like staurosporine, savolitinib, and others.

Conclusions

The prognostic model constructed based on the seven MDSCs-associated lncRNAs showed good application value in assessing prognosis and guiding clinical therapy.